🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Recruitingn/aAges 18 Years - anyAllInternational Extranodal Lymphoma Study Group (IE…
NCT06712459 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Adults aged 18 years or older, regardless of the gender; 2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease); 3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available; 4. Availability of the baseline and follow-up annotations. Exclusion Criteria: * None
💊

What it tests

  • Not listed
📍

Where

7 sites
Columbia University
New York, United States
Universitz Hospitals Leuven
Leuven, Belgium
Hôpital Saint Louis
Paris, France
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Hospital Clínic de Barcelona
Barcelona, Spain
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
University Hospitals Dorset
Bournemouth, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy